Micromet Inc. (MITI) announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia.
The company said, overall, blinatumomab was well tolerated. The most common adverse events included lymphopenia, leucopenia, pyrexia and hypoimmunoglobulinemia. One patient had to discontinue treatment due to a fully reversible neurological adverse event, and was therefore not evaluable for response assessment.
Jan Fagerberg, Micromet's Chief Medical Officer, said, "The data from this completed phase 2 study confirm the high response rate reported earlier this year from the ongoing study. We expect that the positive risk/benefit profile of blinatumomab in acute lymphoblastic leukemia will pave the way for a pivotal trial and a fast track to market in this indication".
Blinatumomab is a CD19-specific, T cell-engaging BiTE antibody designed to direct a patient's own T cells against cancer cells inducing a self-destruction process in cancer cells.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.